SCHEMBL26188331

SCHEMBL26188331

Cc1ccc(CNC(=O)c2cc(S(=O)(=O)N(C)C)ccc2C)cc1C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ATM Q13315 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
F2 P00734 1/20 0.45
HPGD P15428 1/20 0.45
PKM P14618 2/20 0.45
CCR1 P32246 1/20 0.45
POLB P06746 1/20 0.44
NR1H4 Q96RI1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254492 0.88 NPC1 (0.61) NPC1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL26188327 0.87 ALDH1A1 (0.55) NPC1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL24254487 0.85 NPC1 (0.54) NPC1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL34850 0.73 SMN1; SMN2 (0.51) NPC1ALDH1A1KDM4EKMT2ANPSR1
SCHEMBL11281762 0.73 SMN1; SMN2 (0.51) NPC1ALDH1A1KMT2ANPSR1SMN1; SMN2
SCHEMBL19255842 0.72 LMNA (0.57) ALDH1A1KDM4EMEN1KMT2ANPSR1
SCHEMBL26188145 0.72 ALDH1A1 (0.64) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL11179145 0.72 SMN1; SMN2 (0.54) NPC1ALDH1A1KDM4EKMT2ANPSR1
SCHEMBL20489122 0.72 ALDH1A1 (0.67) ALDH1A1KDM4EMEN1KMT2ANPSR1
SCHEMBL11177132 0.72 LMNA (0.48) NPC1ALDH1A1KMT2ANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 NPC1 2293/4885ALDH1A1 1387/4885KDM4E 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.